Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to catch complications early in multiple myeloma patients after transplant

NCT ID NCT05947136

Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a program called PASCA that helps doctors detect and manage complications like high blood pressure, kidney failure, chronic pain, and fatigue in multiple myeloma patients after a stem cell transplant. About 204 adults aged 18 to 70 will be randomly assigned to either the PASCA program or standard care. The goal is to see if proactive screening and early referrals improve long-term health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PASCA program (behavioral intervention: screening and referral for complications)
What this could lead to
If successful, this program could help doctors catch and treat complications like high blood pressure, kidney problems, or fatigue earlier, improving quality of life for multiple myeloma patients after transplant.
What could go wrong
This is a Phase 3 trial, but it tests a care program, not a new drug. The benefit may be small, and results may not apply to all patients or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 204 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old and ≤ 70 years old. 2. Patient treated in an investigation center. 3. Symptomatic multiple myeloma eligible for autologous hematopoietic stem cell transplantation (HSCT). 4. In complete response, complete response, very good complete response, or partial before HSCT. 5. First induction-type treatment (Isa-KRD/dara-VRD/dara-VTD/VRD/VTD/dara-VRD), intensification therapy with melphalan, HSCT, consolidation, maintenance including at least one drug immunomodulator. 6. ECOG performance status WHO ≤ 2. 7. No history or coexistence of other primary cancer apart from basal cell cancer cutaneous 8. Able to understand, read and write French. 9. Having signed and dated the informed consent. Exclusion Criteria: 1. Unable to be monitored for medical, social, family, geographical or psychological, throughout the duration of the study. 2. Deprived of liberty by court or administrative decision. 3. Not affiliated with a health insurance plan. 4. Not having declared an attending physician. 5. Not domiciled in the Auvergne-Rhône-Alpes region or in the Saône-et-Loire department. 6. Not available and/or not willing to participate in the project for the entire duration of the study. 7. Pregnant women, breastfeeding women, people in emergency situations, people incapable of personally giving their consent including adults under guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Complication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Complication Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CENTRE HOSPITALIER UNIVERSITAIRE de MONTPELLIER

    RECRUITING

    Montpellier, 34295, France

  • CH Annecy Genevois

    RECRUITING

    Épagny, 74370, France

  • CHU La Tronche

    RECRUITING

    Grenoble, 38300, France

  • CHU de St-Etienne

    RECRUITING

    Saint-Etienne, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69373, France

  • Le Centre Hôpitaux Nord-Ouest Villefranche-sur-Saône

    RECRUITING

    Villefranche-sur-Saône, 69655, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.